| Bioactivity | MRS2395, an dipivaloyl derivative, is a potent P2Y12 receptor antagonist. MRS2395 inhibits ADP-induced platelet activation with a Ki of 3.6 μM. MRS2395 inhibits cAMP induced by ADP in rat platelets in the presence of PGE1 with an IC50 of 7 µM. MRS2395 enhances platelet dense granule release in response to TRAP-6[1][2]. |
| Name | MRS2395 |
| CAS | 491611-55-3 |
| Formula | C20H30ClN5O4 |
| Molar Mass | 439.94 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bin Xu, et al.Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. J Med Chem. 2002 Dec 19;45(26):5694-709. [2]. Annachiara Mitrugno, et al. Potentiation of TRAP-6-induced platelet dense granule release by blockade of P2Y 12 signaling with MRS2395. Platelets. 2018 Jun;29(4):383-394. |
MRS2395
CAS: 491611-55-3 F: C20H30ClN5O4 W: 439.94
MRS2395, an dipivaloyl derivative, is a potent P2Y12 receptor antagonist. MRS2395 inhibits ADP-induced platelet activati
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.